fbpx

Arthritis Drug Patents Expiring 2024 – 2028

Arthritis Drug Patents List of drug patents expiring from 2024 till 2028

Table of Contents

The arthritis treatment industry is characterized by its intense competitiveness, driving companies to invest significantly in research and development to secure leading arthritis drug patents. Consequently, the expiration of patents for this disease creates significant opportunities for companies specializing in generic medications.

A notable example of the market dynamics in this industry is the case of Humira, a drug developed by AbbVie which became the most lucrative pharmaceutical product in the arthritis treatment sector. AbbVie faced criticism for employing strategies to extend its patent exclusivity and delay the entry of generic and biosimilar competitors into the market. However, in 2016, with the patent expiration, the market started seeing a surge in biosimilar and generic drug competitors, including Amgen’s Amjevita, leading to a decrease in arthritis treatment costs.

Therefore, the significance of tracking patent expirations in this field cannot be overstated. Identifying patents set to expire enables you to enhance and diversify your generic drug portfolios strategically. This approach is crucial for reducing reliance on a single product and mitigating risk through portfolio diversification.

Our comprehensive list provides essential insights, including the active ingredients, applicants, and administration routes of these expiring patents.

This information is vital for generic drug manufacturers planning to enter the arthritis treatment market strategically. For example, knowing the specific route of administration used in the original patented drug is key for formulating generic versions that maintain therapeutic equivalence.

While this article highlights key details, you can obtain the complete PDF version of “Arthritis Drug Patents Expiring in 2024-2028” by simply filling out the form below. Don’t miss this opportunity to stay ahead in the dynamic pharmaceutical landscape.


ARTHRITIS DRUG PATENTS EXPIRING FROM 2024 TO 2028

Colcrys
Colchicine

Applicant:
Takeda Pharmaceuticals USA Inc.

PatentsExpiration Date
US7619004
US7964647
US7964648
US7981938
US8093296
US8093297
US8097655
US8415395
US8415396
3-Dec-2028
6-Oct-2028
6-Oct-2028
6-Oct-2028
6-Oct-2028
6-Oct-2028
6-Oct-2028
6-Oct-2028
6-Oct-2028

Ingredients: Colchicine
Route: Tablet;Oral

Duexis
Famotidine; Ibuprofen

Applicant:
Horizon Medicines LLC.

PatentsExpiration Date
US8067451
US8501228
18-Jul-2026
18-Jul-2026

Ingredients: Famotidine; Ibuprofen
Route: Tablet;Oral

Duzallo
Allopurinol; Lesinurad

Applicant:
Ironwood Pharmaceuticals Inc.

PatentsExpiration Date
US10183012
US8283369
26-Nov-2028
26-Nov-2028

Ingredients: Allopurinol; Lesinurad

Route: Tablet;Oral

Pennsaid
Diclofenac Sodium

Applicant:
Horizon Therapeutics Ireland Dac

PatentsExpiration Date
US825283821-Apr-2028

Ingredients: Diclofenac Sodium
Route: Solution;Topical

Zurampic
Lesinurad

Applicant:
Ironwood Pharmaceuticals Inc.

PatentsExpiration Date
US10183012
US8283369
26-Nov-2028
26-Nov-2028

Ingredients: Lesinurad
Route: Tablet;Oral

Conclusion

As a drug patent expires, it expands the gateway for a number of competitors to enter the market. Tracking these patent expirations beforehand can not only help evaluate business opportunities but also help in refining market entry strategies. 

However, there still lie legal and technology threats and hurdles that a generic company will face depending on the drug they choose for the generic version.

One recent example is the legal dispute involving AbbVie and its arthritis drug, Rinvoq. In November 2023, AbbVie sued several generic drug manufacturers, including Sandoz, Hetero Labs, Aurobindo Pharma, Intas Pharmaceuticals, and Sun Pharmaceutical, for trying to release generic versions of Rinvoq. AbbVie claimed these companies were attempting to bypass Rinvoq’s patent thicket, similar to Humira’s protection strategy. This case demonstrates that even after a drug’s patent expires, the original patent holder may still take steps to defend its product, highlighting the need for detailed research and analysis in developing a generic drug. 

Therefore, if proper research and threat analysis were conducted, developing a generic version of the arthritis drug wouldn’t be as daunting.

How to go about it? 

Well, let’s start with getting in touch by filling out the form below, and we’ll get back to you in no time.

Authored by: Annie Sharma, Editorial Team

Insights by: Nikhil Kaushal, Product Development Team

Share This Article:

Meet The Authors

Related Articles

More Curated Insights For You

Facing A Roadblock On Your Project?

Our Experts Are Here To Help.